BPC-157 vs
TB-500
BPC-157 and TB-500 are two synthetic peptides frequently studied together in regenerative-research literature. BPC-157 is a pentadecapeptide based on a gastric-protein sequence, appearing in cytoprotection and angiogenesis research; TB-500 corresponds to an active region of thymosin beta-4, appearing in actin-binding and cell-migration research. Both are supplied strictly for laboratory research use. This compares what they are and the research pathways they appear in — it makes no claims about effects in humans.
Two peptides, two origins
BPC-157 and TB-500 are among the most frequently studied peptides in the regenerative-research literature, and they are often mentioned together. But they are structurally distinct molecules with quite different origins.
BPC-157 is a synthetic peptide of fifteen amino acids, based on a partial sequence of a protein identified in gastric juice. TB-500 is a synthetic peptide corresponding to an active region of thymosin beta-4, a naturally occurring protein involved in regulating actin. This article compares what they are and the research pathways they appear in. It does not compare outcomes, and it makes no claim about what either compound does in a human being.
The research pathways differ
| Compound | Origin | Research pathways |
|---|---|---|
| BPC-157 | Pentadecapeptide from a gastric-protein sequence | Cytoprotection; angiogenesis; gastrointestinal models |
| TB-500 | Fragment of thymosin beta-4 | Actin binding; cell migration; tissue models |
In short, BPC-157 is most associated in the literature with cytoprotection and the formation of new blood vessels, while TB-500 is most associated with actin regulation and cell movement. These are descriptions of the research areas each appears in — not statements of effect or benefit.
Why they are studied together
Because both sit within the same broad field of regenerative research, they are frequently examined in parallel, and some preparations combine them. Omni Peptides' GLOW preparation contains BPC-157 and TB-500 alongside GHK-Cu, supplied as a single reference preparation for research that examines more than one of these compounds at once. No claim is made about any combined effect.
Research context
Full profiles are set out in the individual research overviews for BPC-157 and TB-500. Both are third-party tested; batch certificates of analysis are available. What an accompanying certificate does and does not establish is covered in our guide to reading a certificate of analysis.
Frequently Asked Questions
They are different molecules from different origins. BPC-157 is a synthetic pentadecapeptide based on a gastric-protein sequence, appearing in cytoprotection and angiogenesis research. TB-500 corresponds to an active region of thymosin beta-4, appearing in actin-binding and cell-migration research. Both are supplied for laboratory research use only.
No. They are structurally distinct peptides with different origins and different associated research pathways. They are, however, frequently studied in the same regenerative-research field and are combined in some preparations.
Both appear in the same broad area of regenerative research, so they are of interest to studies examining more than one such compound in parallel. Our GLOW preparation contains both, alongside GHK-Cu. No claim is made about any combined effect.